文献速递妇科

术后维持性左炔诺孕酮宫内缓释系统与子宫内膜瘤复发:一项随机对照研究

Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study.
PubMed 文献 · Am J Obstet Gynecol · 2017-02-15

该随机对照试验纳入80例子宫内膜瘤行腹腔镜囊肿剥除术后接受6个周期促性腺激素释放激素激动剂治疗的患者,随机分为放置左炔诺孕酮宫内缓释系统组(40例)与对照组(40例)。术后30个月子宫内膜瘤复发率两组无显著差异(25% vs 37.5%,HR 0.60,95%CI 0.27-1.33,P=.209),但干预组痛经复发率更低(HR 0.32,95%CI 0.12-0.83,P=.019)。结论认为长期维持性左炔诺孕酮宫内缓释系统对预防子宫内膜瘤复发无效。

要点

  • 术后30个月子宫内膜瘤复发率干预组25%(10/40)vs对照组37.5%(15/40),无显著差异(HR 0.60,95%CI 0.27-1.33,P=.209)。
  • 干预组痛经复发率更低,估计HR 0.32(95%CI 0.12-0.83,P=.019),30个月痛经复发的需治疗人数为5。
  • 干预组需进一步手术或激素治疗的复发病例数显著低于对照组(1/40,2.5% vs 8/40,20%,P=.031)。

核心结论

  • 长期维持性左炔诺孕酮宫内缓释系统治疗对预防子宫内膜瘤复发无效。

研究设计与样本

  • 2011年5月至2012年3月开展的随机对照试验,纳入80例子宫内膜瘤行腹腔镜囊肿剥除术后接受6个周期促性腺激素释放激素激动剂治疗的患者。
  • 术后随机分为放置左炔诺孕酮宫内缓释系统组(干预组,n=40)与未放置组(对照组,n=40)。
  • 主要结局为术后30个月子宫内膜瘤复发;次要结局包括痛经、CA125水平、非周期性盆腔痛及副作用。

主要发现

  • 术后30个月子宫内膜瘤复发率干预组25%(10/40)vs对照组37.5%(15/40),无显著差异(HR 0.60,95%CI 0.27-1.33,P=.209)。
  • 干预组痛经复发率更低,估计HR 0.32(95%CI 0.12-0.83,P=.019)。
  • 30个月随访期间,干预组痛经视觉模拟评分下降幅度大于对照组(均值±SD,60.8±25.5 vs 38.7±25.9,P<.001,95%CI 10.7-33.5)。
  • 干预组非周期性盆腔痛视觉模拟评分下降幅度大于对照组(39.1±10.9 vs 30.1±14.7,P=.014,95%CI 1.9-16.1)。
  • 干预组CA125下降幅度大于对照组(中位数[四分位距],-32.1[-59.1至14.9] vs -15.6[-33.0至5.0],P=.001)。

临床怎么用

  • 作者结论认为长期维持性左炔诺孕酮宫内缓释系统治疗对预防子宫内膜瘤复发无效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: According to 3 randomized trials, the levonorgestrel-releasing intrauterine system significantly reduced recurrent endometriosis-related pelvic pain at postoperative year 1. Only a few studies have evaluated the long-term effectiveness of the device for preventing endometrioma recurrence, and the effects of a levonorgestrel-releasing intrauterine system as a maintenance therapy remain unclear. OBJECTIVE: The objective of the study was to evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing postoperative endometrioma recurrence. STUDY DESIGN: From May 2011 through March 2012, a randomized controlled trial including 80 patients with endometriomas undergoing laparoscopic cystectomy followed by six cycles of gonadotropin-releasing hormone agonist treatment was conducted. After surgery, the patients were randomized to groups that did or did not receive a levonorgestrel-releasing intrauterine system (intervention group, n = 40, vs control group, n = 40). The primary outcome was endometrioma recurrence 30 months after surgery. The secondary outcomes included dysmenorrhea, CA125 levels, noncyclic pelvic pain, and side effects. RESULTS: Endometrioma recurrence at 30 months did not significantly differ between the 2 groups (the intervention group, 10 of 40, 25% vs the control group 15 of 40, 37.5%; hazard ratio, 0.60, 95% confidence interval, 0.27-1.33, P = .209). The intervention group exhibited a lower dysmenorrhea recurrence rate, with an estimated hazard ratio of 0.32 (95% confidence interval, 0.12-0.83, P = .019). Over a 30 month follow-up, the intervention group exhibited a greater reduction in dysmenorrhea as assessed with a visual analog scale score (mean ± SD, 60.8 ± 25.5 vs 38.7 ± 25.9, P < .001, 95% confidence interval, 10.7-33.5), noncyclic pelvic pain visual analog scale score (39.1 ± 10.9 vs 30.1 ± 14.7, P = .014, 95% confidence interval, 1.9-16.1), and CA125 (median [interquartile range], -32.1 [-59.1 to 14.9], vs -15.6 [-33.0 to 5.0], P = .001) compared with the control group. The number-needed-to-treat benefit for dysmenorrhea recurrence at 30 months was 5. The number of recurrent cases requiring further surgical or hormone treatment in the intervention group (1 of 40, 2.5%, 95% confidence interval, -2.3% to 7.3%) was significantly lower than that in the control group (8 of 40, 20%, 95% confidence interval, 7.6-32.4%; P = .031). CONCLUSION: Long-term maintenance therapy using a levonorgestrel-releasing intrauterine system is not effective for preventing endometrioma recurrence.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chen YJ, Hsu TF, Huang BS, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017. PMID: 28209488. doi:10.1016/j.ajog.2017.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。